Dr. Kim received his PhD on 1996 from the Department of Pharmaceutical Sciences, University of Tokyo, and Tokyo, Japan. He completed his postdoctoral fellowship training in both academic and biotechnology & pharmaceutical companies in Japan, South Korea and USA. He has experience in several scientific backgrounds in the fields of molecular, neurobiology, cancer pharmacology such as multidrug resistance in solid cancers, vaccine development for AD and infectious disease, and innate immunity in AD. He has been widely respected for his discovery with regard to the development of antibody against beta amyloid in Alzheimer disease (AD) which develops novel antibody as counteract neurotoxicity due to misfolding of beta amyloid protein and demeliolate of Abeta to neuronal cells which results in memory loss. Alzheimer's disease (AD) is a growing social concern and the most common type of dementia in the elderly along with genetic and environmental risk variations which accelerates oxidative stress mediated production of toxic and misfolding protein such as beta amyloid which slowly causes progressive neurodegenerative disease. Even though there is a growing life expectancy (demographic transition) with better medicine, prognostic, diagnostic tool and advocacy of public health prevention, there are currently 4 million Americans diagnosed with AD and approximately more than 500,000 new cases per year. Dr. Kim’s research interest will serve as a proof of principle to demonstrate whether our novel immune gene therapy modality with good epitope is effective in treating an animal model of AD. Since 2008, Dr. Kim has also participates in the Rutgers CounterACT Center of excellence (PI. Dr. Heck) contributing his expertise in molecular biology and pharmaceutical biologics to the group. Dr. Kim believes that his insights into the complexity of commercial development and production of biologics has been helpful in speeding approaches to product selection and may have assisted the Center in avoiding costly mistakes. He has also developed and conducted mechanism-based screening assay to evaluate drug candidates, assisted in the development of animal models and adapted techniques for the evaluation of potential drug product efficacy. Currently he is refining animal models for mustard toxicity and adapting the technology for exploring microRNA as regulators, and then developed for vaccine production toward enhance wound healing and limit toxicity resulting from exposure to mustard vesicants as counteract measures. He is gratified that many of the students under his mentorship have moved on to join emerging biotechnology entities and important biologics such as single chain antibody or explore biomarker to detection early or therapy in diseases such as Skin cancer, neurodegenerative disorders including heavy metal toxicity.
